Pricing
  1. JP-listed companies
  3. Financials
  4. Revenue

(130A)

Market cap
¥3.1B
P/E ratio
-5.4x
Veritas In Silico develops small-molecule drugs targeting messenger RNA using its ibVIS platform, partnering with major pharmaceutical companies like Takeda and Shionogi.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
Dec 31, 202591-53.18%
Dec 31, 2024195-45.99%
Dec 31, 2023360+101.54%
Dec 31, 2022179+201.37%
Dec 31, 202159+345.22%
Dec 31, 202013-26.70%
Dec 31, 201918+8.88%
Dec 31, 201817

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat